Key Highlights

• Shares trading up 2.27% pre-market, adding $0.67 to reach $30.17, extending Friday's regular-session gain

• European Commission granted Marketing authorization for DAYBU, the first and only approved treatment for Rett syndrome neurobehavioral symptoms in the EU

• Approval covers adults and pediatric patients aged five and older across all 27 EU member states plus Iceland, Liechtenstein, and Norway

• News adds to recent momentum after the company's second-quarter results beat Earnings estimates, with Revenue up 16.4% year-over-year

First Approved Rett Syndrome Treatment in the EU

Acadia Pharmaceuticals (NASDAQ:ACAD) shares are trading higher in pre-market activity Monday, up 2.27% to $30.17, extending Friday's gain after the European Commission granted marketing authorization for DAYBU (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five and older. The approval makes DAYBU the first and only treatment authorized for Rett syndrome anywhere in the European Union.

Acadia is a San Diego-based biopharmaceutical company focused on discovering, developing, and commercializing novel medicines for central nervous system disorders and rare diseases. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome, while its late-stage pipeline includes programs in Alzheimer's disease psychosis and Lewy body dementia psychosis alongside earlier-stage programs in other underserved neuropsychiatric and neuro-rare disease indications.

A Rare, Underserved Condition Gets a New Option

Rett syndrome is a rare, complex neurodevelopmental disorder occurring in roughly one of every 10,000 to 15,000 female births worldwide, typically caused by a genetic mutation on the MECP2 gene. The condition places a substantial physical, psychological, and economic burden on patients and caregivers, with treatment Options in the EU previously nonexistent. The authorization is based primarily on results from the Phase 3 LAVENDER study, which showed statistically significant and clinically meaningful improvements in core features of the condition. With approval now granted across all 27 EU member states plus Iceland, Liechtenstein, and Norway, Acadia will next begin pricing and reimbursement negotiations with national authorities.

The approval adds to recent momentum for the stock, which reported second-quarter results beating estimates, with Earnings Per Share of $0.18 against a $0.07 estimate and revenue up 16.4% year-over-year to $308 million. The move also comes amid a broader biotech sector rally, with benchmarks like the iShares Biotechnology ETF pushing toward record highs.

Looking Ahead

Acadia's pre-market gain reflects a genuine regulatory milestone, the first EU approval for a Rett syndrome treatment, layered on top of recent earnings strength and favorable sector sentiment. With pricing and reimbursement negotiations now beginning across European markets, the stock's next moves will likely hinge on the pace of those discussions and continued execution across its broader CNS and rare disease pipeline.